Barinthus Biotherapeutics (BRNS) Total Current Liabilities (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Total Current Liabilities came in at $12.0 million in Q1 2026, little changed YoY from $12.0 million in Q1 2025, and up 19.79% on a QoQ basis from $10.0 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Total Current Liabilities (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Total Current Liabilities data on file, last reported at $12.0 million in Q1 2026.
- Quarterly Total Current Liabilities changed 0.21% year-over-year to $12.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.0 million (changed 0.21% YoY) and the FY2025 annual result came in at $10.0 million, down 36.02% from the prior year.
- Total Current Liabilities climbed to $12.0 million in Q1 2026, from $10.0 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $18.6 million in Q3 2023 to a low of $10.0 million in Q4 2025.
- A 5-year average of $13.3 million and a median of $12.6 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 120.2% — and 2025, when it plunged 36.02%.
- Tracing BRNS's Total Current Liabilities over 5 years: stood at $12.2 million in 2022, then grew by 2.91% to $12.6 million in 2023, then climbed by 24.28% to $15.7 million in 2024, then sank by 36.02% to $10.0 million in 2025, then gained by 19.79% to $12.0 million in 2026.
- The last three Total Current Liabilities figures came in at $12.0 million (Q1 2026), $10.0 million (Q4 2025), and $10.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | 630.93 Mn |
| 10 | Barinthus Biotherapeutics | 25.73 Mn | 25.73 Mn | - | 11.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.42 Mn |
| Mar 31, 2026 | 12.00 Mn |
| Dec 31, 2025 | 10.02 Mn |
| Sep 30, 2025 | 10.80 Mn |
| Jun 30, 2025 | 12.73 Mn |
| Mar 31, 2025 | 11.98 Mn |
| Dec 31, 2024 | 15.66 Mn |
| Sep 30, 2024 | 15.07 Mn |
| Jun 30, 2024 | 15.59 Mn |
| Mar 31, 2024 | 12.84 Mn |
| Dec 31, 2023 | 12.60 Mn |
| Sep 30, 2023 | 18.57 Mn |
| Jun 30, 2023 | 12.11 Mn |
| Mar 31, 2023 | 11.99 Mn |
| Dec 31, 2022 | 12.24 Mn |
| Sep 30, 2022 | 14.03 Mn |
| Jun 30, 2022 | 12.17 Mn |
| Mar 31, 2022 | 16.48 Mn |
| Dec 31, 2021 | 11.16 Mn |
| Sep 30, 2021 | 6.37 Mn |